Novartis launched an initiative to help patients treat COVID-19 in low-income and lower-middle-income countries (LIC; LMIC) by offering access to affordable medicines to treat the major symptoms of COVID-19. Novartis has identified this as a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and can lead to death in some people. Health systems in these countries, much like in the developed world, are under strain and stress. Moreover, they have declared the intent to provide all this at zero profit. Of course, the devil is always in the details, and the TrialSite will certainly monitor how this program unfolds. But this announcement represents a positive move on the part of the Basel, Switzerland-based company to leverage its capital, talent, products, and distribution network to help health care providers worldwide slow down this horrific virus. An example of “Big Pharma” is getting on the right side of history. Will other companies follow their lead?
This global pandemic has placed extreme pressure on healthcare systems in low and lower-income countri...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).